More information: Sergio Escamilla et al, Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients, Alzheimer's & Dementia (2024). DOI: 10.1002/alz.14125 ...

Medically reviewed by Femi Aremu, PharmD Dementia is a loss of brain function that affects memory, thinking, judgment, behavior, and language. Alzheimer's disease is the most common type of dementia.

it’s known as early onset Alzheimer’s disease (EOAD). Memantine is an NMDA receptor antagonist. These medications work by blocking N-methyl-D-aspartate (NMDA) receptors and reducing excess ...

Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue.

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

submission for AXS-05 in Alzheimer’s disease agitation. AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 ...

Samantha Schwarz, a doctoral candidate in the neuroscience program, won the second place prize of $1,500 in UB’s ninth annual Three Minute Thesis (3MT) competition.

in regulating the synaptic response downstream of NMDA receptor activation. GSK3β has been implicated in neurological disorders such as Alzheimer's disease and mood disorders; however its roles ...

AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor under development for the ...